Vnitřní lékařství 8/2020

PŘEHLEDOVÉ ČLÁNKY Heparínom indukovaná trombocytopénia a aktuálne možnosti liečby – prehľad literatúry E46 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2020; 66(8): e39–e46 /  www.casopisvnitrnilekarstvi.cz 30. Warkentin TE, Greinacher A. Heparin‑induced thrombocytopenia and cardiac surge‑ ry. Ann Thorac Surg 2003; 76: 2121–2131. 31. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) Score: a no‑ vel pre‑test probability model for heparin‑induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010; 8: 2642–2650. 32. Pouplard C, May MA, Regina S, et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin‑dependent antibodies. Br J Haematol 2005; 128: 837–841. 33. Nuttall GA, Oliver jr. WC, Santrach PJ, et al. Patients with a history of type II heparin­ ‑induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopul‑ monary bypass: a prospective observational case series. Anesth Analg 2003; 96: 344–350. 34. Lillo‑Le Louët A, Boutouyrie P, Alhenc‑Gelas M, et al. Diagnostic score for heparin- induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2004; 2: 1882–1888. 35. Shantsila E, Lip GYH, Chong BH. Heparin‑induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 2009; 135: 1651–1664. 36. Warkentin TE, Levine MN, Hirsh J, et al. Heparin‑induced thrombocytopenia in pa‑ tients treated with low‑molecular‑weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330–1335. 37. Ahmed I, Majeed A, Powell R. Heparin‑induced thrombocytopenia: diagnosis and ma‑ nagement update. Postgrad Med J 2007; 83: 575–582. 38. Arepally GM, Ortel TL. Clinical practice. Heparin‑induced thrombocytopenia. N Engl J Med 2006; 355: 809–817. 39. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T’s) for the dia‑ gnosis of heparin‑induced thrombocytopenia in two clinical settings. J Thromb Hae‑ most 2006; 4: 759–765. 40. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin­ ‑induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163: 2518–2524. 41. Lazúr J. Heprínom indukovaná trombocytopénia. Interná med 2019; 19: 51–54. 42. Kubisz P, Hollý P, Staško J. Heparínom indukovaná trombocytopénia. In: Štvrtinová V et al. Venózny tromboembolizmus. Bratislava: SAP, 2018, 388 s. 43. Brieger DB, Mak KH, Kottke‑Marchant K, et al. Heparin‑induced thrombocytopenia. J Am Coll Cardiol 1998; 31: 1449–1459. 44. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guide‑ lines for management of venous thromboembolism: heparin‑induced thrombocytope‑ nia. Blood Adv 2018; 2: 3360–3392. 45. He Y, He H, Liu D, et al. Fondaparinux in a critically ill patient with heparin‑induced thrombocytopenia. Medicine 2018; 97: 37. 46. Linkins LA, Hu G, Warkentin TE. Systematic review of fondaparinux for heparin‑induced thrombocytopenia: When there are no randomized controlled trials. Res Pract Thromb Haemost 2018; 2: 678–683. 47. Al‑Eidan FAS, Alrawkan S, Alshammary H, et al. Comparison of argatroban and fonda‑ parinux for the management of patients with isolated heparin‑induced thrombocytope‑ nia. Ann Hematol 2018; 47: 12. 48. Skelley JW, Kyle JA, Roberts RA. Novel oral anticoagulants for heparin‑induced throm‑ bocytopenia. J Thromb Thrombolysis 2016; 42: 172–178. 49. SokolJ,NehajF,MokánM,etal.Novéperorálneantikoagulanciá.Martin:Osveta.2018.s.266. 50. Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban - an oral, direct Factor Xa inhibi‑ tor - has potential for the management of patients with heparin‑induced thrombocyto‑ penia. Br J Haematol 2008; 143: 92–99. 51. Walenga JM, Prechel M, Hoppensteadt D, et al. Apixaban as an alternate oral anticoa‑ gulant for the management of patients with heparin‑induced thrombocytopenia. Clin Appl Thromb Hemost 2013; 19: 482–487. 52. Linkins LA, Warkentin TE, Pai M, et al. Design of the rivaroxaban for heparin‑induced thrombocytopenia study. J Thromb Thrombolysis 2014; 38: 485–492. 53. Aljabri A, Huckleberry Y, Karnes JH, et al. Cost‑effectiveness of anticoagulants for suspected heparin‑induced thrombocytopenia in the United States. Blood 2016; 128: 3043–3051. 54. Linkins LA, Warkentin TE, Pai M, et al. Abstract number 3468 Rivaroxaban for Treatment of Suspected or Confirmed Heparin‑Induced Thrombocytopenia Study. American Socie‑ ty of Hematology 57th annual meeting Orlando FL, 2016. 55. Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood 2017; 130: 1104–1113. 56. Shatzel JJ, Crapster‑Pregont M, Deloughery TG. Non‑vitamin K antagonist oral anti‑ coagulants for heparin‑induced thrombocytopenia. A systematic review of 54 reported cases. Thromb Haemost 2016; 116: 397–400. 57. Kunk P, Macik BG, Brown J. Abstract number 3547 Non‑Warfarin Oral Anticoagulants in Heparin‑Induced Thrombocytopenia. American Society of Hematology 57 th annual meeting Orlando FL, 2015. 58. Ng HJ, Than H, Teo EC First experiences with the use of rivaroxaban in the treatment of heparin‑induced thrombocytopenia. Thromb Res 2015; 135: 205–207. 59. Mirdamadi A Dabigatran, a direct thrombin inhibitor, can be a life‑saving treatment in heparin‑induced thrombocytopenia. ARYA Atheroscler 2013; 9: 112–114. 60. Hantson P, Lambert C, Hermans C. Rivaroxaban for arterial thrombosis related to heparin‑induced thrombocytopenia. Blood Coagul Fibrinolysis 2015; 26: 205–206. 61. Sartori M, Favaretto E, Cini M, et al. Rivaroxaban in the Treatment of Heparin‑Induced Thrombocytopenia. J Thromb Thrombolysis 2015; 40: 392–394. 62. Larsen PB, Jørgensen M, Friis‑Hansen L, et al. Apixaban used for the management of heparin‑induced thrombocytopenia in a 72-year‑old woman with lung cancer. Clin Case Rep 2015; 3: 987–989. 63. Sharifi M, Bay C, Vajo Z, et al. New oral anticoagulants in the treatment of heparin­ ‑induced thrombocytopenia. Thromb Res 2015; 135: 607–609. 64. Abouchakra L, Khabbaz Z, Abouassi S, et al. Rivaroxaban for treatment of heparin­ ‑induced throm- bocytopenia after cardiac surgery: A case report. J Thorac Cardiovasc Surg 2015; 150: e19–e20. 65. Kopolovic I, Warkentin TE. Progressive thrombocytopenia after cardiac surgery in a 67-year‑old man. CMAJ 2014; 186: 929–933. 66. Sninská Z, Chudej J, Guman T, et al. Primárna imúnna trombocytopénia: princípy klasi‑ fikácie, diagnostiky a liečby. Bratislava: GlaxoSmithKline Slovensko, 2014, 57 s. 67. Majdák P, Kubík jr. J, Harmátová L. Prípad vlajúceho infikovaného trombu v. jugularis interna, septických pneumónií a heparínom indukovanej trombocytopénie. Vnitř Lék 2011; 57: 117–121. 68. Sárník S, Hofírek I. Opakovaná lokální trombolýza u poranení a trombózy axilární a pod‑ klíckové zíly. Vnitř Lék 2009; 55: 1102–1104. 69. Dulíček P, Chrobák L. Trombocytopenie indukovaná heparinem.